Back to search

Article

The Effects of Nusinersen Treatment on Respiratuar Status of Children with Spinal Muscular Atrophy

2021-11-15

Abstract excerpt

<h4>Introduction: </h4> Pulmonary involvement is the main prognostic factor in children with spinal muscular atrophy (SMA). Nusinersen, a new treatment modality, is being evaluated in recent studies, although the respiratory part has not yet been clarified. We aimed to reveal the effects of nusinersen on the respiratory functions of patients with spinal muscular atrophy (SMA). Methods : In this single-center rando...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
334efa42-0d36-5c20-aff6-dfd0e00a07ea
DOI
10.22541/au.163699817.79769760/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Effects of Nusinersen Treatment on Respiratuar Status of Children with Spinal Muscular AtrophyDOI 10.22541/au.163699817.79769760/v1
Respiratory effects of nusinersen treatment in pediatric patients with spinal muscular atrophy types 2 and 3Semantic proximity
The respiratory impact of novel therapies for spinal muscular atrophy.Semantic proximity
Treatment of 5q-spinal muscular atrophy with nusinersen in Southern China: A single center retrospective studySemantic proximity
SPINAL MUSCULAR ATROPHY: CLINICAL CHARACTERIZATION AND EVOLUTION AFTER TREATMENT WITH NEW MODIFYING THERAPIESSemantic proximity
Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in western ChinaSemantic proximity
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.Semantic proximity
Effect of nusinersen after three years of treatment in 61 young children with SMA type 1 or 2: a French real-life observational studySemantic proximity
Clinical Characteristics, Genotypes, and Treatment Outcomes in 133 Patients With Spinal Muscular Atrophy: A Retrospective Cohort.Semantic proximity
Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type.Semantic proximity
Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1)Semantic proximity
Gene-Based Therapy for the Treatment of Spinal Muscular Atrophy Types 1 and 2 : A Systematic Review and Meta-AnalysisSemantic proximity
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studySemantic proximity
Select a neighboring publication to make it the new centre.